The effects of A2B receptor modulators on vascular endothelial growth factor and nitric oxide axis in chronic...

Area of Science:

• Nephrology
• Pharmacology
• Molecular Biology

Background:

• Cyclosporine (CsA) administration induces nephropathy, characterized by impaired renal function and altered levels of key signaling molecules.
• Vascular Endothelial Growth Factor (VEGF) and Nitric Oxide (NO) play crucial roles in maintaining kidney health and function.
• The role of adenosine A2B receptors (A2B ARs) in CsA-induced nephropathy is not fully understood.

Purpose of the Study:

• To investigate the therapeutic potential of adenosine A2B receptor modulators in mitigating CsA nephropathy.
• To examine the effects of A2B AR modulators on VEGF and NO levels in the context of CsA-induced kidney damage.

Main Methods:

• CsA-induced nephropathy model in rats.
• Measurement of serum creatinine, creatinine clearance, urinary albumin excretion, and blood urea nitrogen to assess renal function.
• Assessment of kidney pathology scores.
• Quantification of VEGF and NO levels in kidney tissue.
• Analysis of mRNA expression for A2B AR and VEGF.

Main Results:

• CsA administration for 5 weeks resulted in significant renal dysfunction and reduced renal VEGF and NO levels.
• A2B AR mRNA expression was upregulated in CsA-treated animals.
• In vivo administration of an A2B AR agonist increased renal VEGF and improved renal function in CsA-treated rats.
• The effects of the A2B AR agonist were blocked by a selective A2B AR antagonist (MRS1754).

Conclusions:

• Adenosine A2B receptor modulators demonstrate a therapeutic effect in reversing CsA-induced nephropathy.
• Modulation of A2B ARs impacts renal VEGF and NO levels, contributing to the observed renoprotective effects.
• A2B AR modulators represent a promising therapeutic strategy for managing CsA nephropathy.